$ Value
$0
Shares
8,425
Price
$0
Filed
Jun 24
Insider
Name
Valantine Hannah
Title
—
CIK
0001855608
Roles
Transaction Details
Transaction Date
2025-06-20
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
8,425
Footnotes
Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. | Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. | One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
Filing Info
Valantine Hannah's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-06-26 | BBIO | ▼ | $39K |
| 2025-06-26 | BBIO | ▼ | $68K |
| 2025-06-26 | BBIO | ▼ | $18K |
| 2025-06-26 | BBIO | ▼ | $83K |
| 2025-06-20 | BBIO | A | $0 |
| 2025-06-20 | BBIO | A | $0 |
| 2025-06-18 | CDNA | ▼ | $203K |
| 2025-06-13 | CDNA | A | $0 |
| 2025-06-10 | BBIO | M | $72K |
| 2025-06-10 | BBIO | ▼ | $172K |
Other Insiders at BBIO (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Kumar Neil
Chief Executive Officer
|
— | $6.0M | 2026-04-10 |